For how we live.
Stargardt disease, the most common inherited macular dystrophy, has no approved treatment. In the 50-patient TEASE-1 trial, gildeuretinol slowed atrophic lesion growth by a fraction of a millimetre a year.
In South Kivu, ophthalmologists examined 310 patients with confirmed clade Ib mpox at four time points. Periorbital lesions and severe acute malnutrition tripled the risk of ocular involvement.
Three of the four Yamanaka factors, delivered to one eye and switched on with an antibiotic for eight weeks. The mouse data are striking; the trial is a safety study and will not measure ageing.
The trials that made eye vitamins a standard recommendation enrolled only people who already had substantial disease. In AREDS2, neither omega-3 nor lutein beat placebo on the primary endpoint.
EyeFM was tested as an assistant to 16 ophthalmologists screening 668 high-risk patients in China. Patients in the AI arm also followed referral advice more often.
Off-the-shelf features from two published models matched retinal scans to the right patient 78% to 86% of the time. Fine-tuned for the task, one model reached 99.5% on OCT.